西隴科學(002584.SZ)控股公司簽署《解放軍總院醫療設備採購協議》
格隆匯3月2日丨西隴科學(002584.SZ)公佈,公司控股公司上海福君基因生物科技有限公司(“上海福君”,乙方)於近日與中國人民解放軍總醫院第七醫學中心(甲方)簽署了《解放軍總院醫療設備採購協議》。
甲方同意購買、乙方同意出售下述產品,協議總價為85萬元。

福君基因的FLIMS系統是國際領先的二代測序實驗室管理系統,集成了NGS實驗管理、生物信息流程與解讀系統,FLIMS系統的應用可以更好地幫助醫院搭建遺傳病診斷的流程與標準。上海福君與解放軍總醫院的合作,可以推進中國標杆醫院在遺傳病診斷上的智能化應用,加速福君基因與醫院在二代測序領域的深度合作,同時對於福君基因市場品牌的提升有積極的作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.